Spectroscopic and Theoretical Study of CuI Binding to His111 in the Human Prion Protein Fragment 106-115 by Arcos López, Trinidad et al.
Spectroscopic and Theoretical Study of CuI Binding to His111 in the
Human Prion Protein Fragment 106−115
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Rafael Grande-Aztatzi,† Claudio O. Fernańdez,§ Britt Hedman,∥ Keith O. Hodgson,‡,∥ Alberto Vela,†
Edward I. Solomon,*,‡,∥ and Liliana Quintanar*,†
†Departamento de Química, Cinvestav, Gustavo A. Madero, 07360 Mex́ico
‡Department of Chemistry, Stanford University, Stanford, California 94395, United States
∥Stanford Synchrotron Radiation Lightsource (SSRL), SLAC, Stanford University, Menlo Park, California 94025, United States
§Max Planck Laboratory for Structural Biology, Chemistry and Molecular Biophysics of Rosario (MPLbioR, UNR-MPIbpC) and
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ABSTRACT: The ability of the cellular prion protein (PrPC)
to bind copper in vivo points to a physiological role for PrPC in
copper transport. Six copper binding sites have been identiﬁed
in the nonstructured N-terminal region of human PrPC.
Among these sites, the His111 site is unique in that it contains
a MKHM motif that would confer interesting CuI and CuII
binding properties. We have evaluated CuI coordination to the
PrP(106−115) fragment of the human PrP protein, using
NMR and X-ray absorption spectroscopies and electronic
structure calculations. We ﬁnd that Met109 and Met112 play
an important role in anchoring this metal ion. CuI
coordination to His111 is pH-dependent: at pH >8,
2N1O1S species are formed with one Met ligand; in the range of pH 5−8, both methionine (Met) residues bind to CuI,
forming a 1N1O2S species, where N is from His111 and O is from a backbone carbonyl or a water molecule; at pH <5, only the
two Met residues remain coordinated. Thus, even upon drastic changes in the chemical environment, such as those occurring
during endocytosis of PrPC (decreased pH and a reducing potential), the two Met residues in the MKHM motif enable PrPC to
maintain the bound CuI ions, consistent with a copper transport function for this protein. We also ﬁnd that the physiologically
relevant CuI-1N1O2S species activates dioxygen via an inner-sphere mechanism, likely involving the formation of a copper(II)
superoxide complex. In this process, the Met residues are partially oxidized to sulfoxide; this ability to scavenge superoxide may
play a role in the proposed antioxidant properties of PrPC. This study provides further insight into the CuI coordination
properties of His111 in human PrPC and the molecular mechanism of oxygen activation by this site.
1. INTRODUCTION
Transmissible spongiform encephalopathies are a group of
neurodegenerative disorders that include scrapie in sheep,
bovine spongiform encephalopathy, chronic wasting disease in
elk and deer, and Creutzfeldt−Jakob disease in humans.1 The
infectious agent is an abnormally folded isoform of cellular
prion protein (PrPC), designated as PrPSc. This misfolded
protein is rich in β-sheet structure, insoluble, and protease-
resistant and possesses a tendency to polymerize into amyloid
aggregates.2,3 These ﬁbrils accumulate as plaques in the nervous
system and have been associated with the induction of neuronal
death.4,5 PrPSc propagates itself by autocatalytic conversion of
the normal cellular form.6 PrPC is a cell surface glycoprotein
expressed throughout the body but mainly found in the central
nervous system of all mammals and avian species.1,7
After posttranslational modiﬁcation, human PrP comprises
209 amino acids PrP(23−231).8,9 The N-terminal region of
PrPC is largely unstructured, while the C-terminal region has a
globular structure with three α-helices and two short β-
sheets.10,11 The physiological role of PrPC has not been
determined; however, it has been proposed to participate in the
allosteric function, signal transduction, cell−cell adhesion, and
suppression of apoptosis.12−17 The ability of PrPC to bind CuII
in vivo has led to the proposals that it may play a role in copper
sensing, buﬀering, and/or transport.16−20 Furthermore, cellular
studies show that copper or zinc binding to PrPC induces its
endocytosis.21−23 It has been established that PrPC can bind up
to six CuII ions in its ﬂexible N-terminal region.24,25 CuII
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coordination to the N-terminal region of PrPC as well as related
synthetic peptides have been extensively studied.26 Because
these copper binding sites are unstructured, the study of
peptide fragments has been a successful approach to studying
copper binding to PrP. In the octarepeat region (OR), a
domain comprised of four tandem repeats of eight amino acids
with the sequence PHGGGWGQ, CuII sites are populated in
response to the pH and CuII concentration.27
Outside the OR region, two sites have been identiﬁed; these
are associated with His96 and His111. The His96 CuII site can
adopt a 3N1O or 4N equatorial coordination mode, with a pKa
value of 7.8 for conversion between these species.28,29
Regarding CuII binding to His111, several proposals of
coordination modes have been suggested.30−32 In our previous
study, CuII-PrP(106−115) complexes were characterized using
diﬀerent spectroscopic techniques [absorption, circular dichro-
ism (CD), and electron paramagnetic resonance (EPR)] in
combination with electronic structure calculations.33 This study
shows a pH-dependent CuII-PrP(106−115) coordination mode
with a pKa value of 7.5 (structures given in Scheme 1).
Several reports have suggested that copper bound to PrP is
redox-active. Electrochemical measurements of copper bound
to the OR region have concluded that the low-occupancy
copper binding mode [E1/2(Cu
II-OR/CuI-OR) = 0.323 V vs
NHE] cannot reduce dioxygen to hydrogen peroxide [E1/2(O2/
H2O2) = 0.296 V vs NHE], while the high-occupancy copper
binding mode [E1/2(Cu
II
4-OR/Cu
I
4-OR) = 0.172 V vs NHE]
can.34 With respect to the N-terminal His111 site, spin-trapping
and NBT/Formazan experiments with the PrP(106−126) and
PrP(106−114) fragments suggested that these peptides are also
capable of hydrogen peroxide or superoxide production in the
presence of CuII, ascorbic acid, and dioxygen.35,36 While the
nature of the CuII coordination properties of the N-terminal
region of the PrP protein has been widely explored, studies of
its CuI binding properties have been limited.35,37 Unlike the
other sites, the His111 binding site contains two adjacent
methionine (Met) residues, which could provide good ligands
for CuI and promote interesting redox behavior for this site. In
fact, extended X-ray absorption ﬁne structure (EXAFS) studies
have demonstrated CuI−S interactions in the CuI complexes of
PrP(106−114) and PrP(91−126) fragments at pH 7.4.35
However, at this pH, the EXAFS spectra would have
contributions from diﬀerent protonation states of the complex
(vide infra), obscuring the coordination mode assignments.
In this study, we used diﬀerent spectroscopic techniques (X-
ray absorption spectroscopy and NMR) in combination with
electronic structure calculations to elucidate the coordination
modes involved in CuI binding to His111 in the PrP(106−115)
fragment. A detailed pH study of the CuI binding properties of
this fragment has allowed us to identify species that would be
physiologically relevant. We have also evaluated the oxygen
reactivity of these CuI species, identifying speciﬁc sites for
copper-catalyzed oxidation. The roles of Met109 and Met112
in CuII and CuI coordination, as well as oxygen activation have
been evaluated.
2. EXPERIMENTAL SECTION
2.1. Peptide Synthesis. Peptides KTNMKHMAGA [PrP(106−
115)], KTNAKHMAGA [PrP(106−115)M109A], KTNMKHAAGA
[PrP(106−115)M112A], and KTNAKHAAGA [PrP(106−115)-
M109&M112A] were prepared by solid-phase ﬂuorenylmethoxycar-
bonyl (Fmoc) methods, using a Fmoc-Rink amide MBHA resin, as
previously described.33,38,39 All peptides were acetylated at the amino
terminus and amidated in the carboxyl terminal. Peptides were puriﬁed
by semipreparative reversed-phase high-performance liquid chroma-
tography (HPLC). The ﬁnal purity was determined by analytical
HPLC and was found to be >95%. The molecular mass of each
peptide was conﬁrmed by electrospray ionization mass spectroscopy.
2.2. K-Edge X-ray Absorption Spectroscopy (XAS). Sample
Preparation. Copper(II) peptide complexes were prepared either at a
2 mM peptide concentration with 0.5 equiv of CuII (at pH 6.5) or 1
mM peptide with 0.8 equiv of CuII at pH 8.5, in a mixture of 20 mM 2-
(N-morpholino)ethanesulfonic acid (MES) buﬀer with 20 mM N-
ethylmorpholine (NEM) and 50% glycerol; the pH was adjusted by
adding small volumes of NaOH or HCl. The nature of the copper(II)
peptide complexes was probed by electron paramagnetic resonance
(EPR) spectroscopy, yielding g∥ and A∥ values that are consistent with
those previously reported.33 The copper(I) peptide complexes were
obtained upon reduction of the copper(II) peptide complexes with
100 equiv of ascorbic acid (adjusted to the corresponding pH), under
anaerobic conditions. The reduced complexes were characterized by
EPR, and in all cases, they were found to contain less than 3% of the
residual CuII species (Figure S1 in the Supporting Information, SI).
XAS Data Collection. The Cu K-edge XAS data were collected at
the SSRL on the unfocused 20-pole, 2.0-T wiggler beamline 7-3 under
storage ring parameters of 3 GeV and 300−350 or 500 mA. A
rhodium-coated premonochromator ﬂat bent mirror was used for
harmonic rejection and vertical collimation. A Si(220) double-crystal
monochromator was used for energy selection. The samples were
loaded into 2 mm Lucite XAS cells with 38 μm Kapton windows and
maintained at a constant temperature of ∼10 K during data collection
using an Oxford Instruments CF 1208 continuous-ﬂow liquid-helium
cryostat. A Canberra Ge 30-element solid-state array detector was used
to collect Cu Kα ﬂuorescence signals, using a Soller slit and a zinc ﬁlter
inserted between the sample and detector. The sample was positioned
at 45° to the incident beam. Internal energy calibration was
accomplished by simultaneous measurement of the absorption of a
copper foil placed between two ionization chambers located after the
sample. The ﬁrst inﬂection point of the foil spectrum was assigned to
8980.3 eV. Extended X-ray absorption ﬁne structure (EXAFS) data are
reported to k = 12.8 Å−1 in order to avoid interference from the Zn K-
edge. No photodamage was observed to CuI samples, and thus all of
the scans were used in the ﬁnal average. Each data set includes an
average of 7−27 scans. Data from CuII samples were collected on four
physically separate spots on the sample cells with 2−4 scans/spot to
minimize the eﬀect of photoreduction.
XAS Data Analysis. The energy-calibrated and averaged data were
processed by ﬁtting a second-order polynomial to the preedge region
and subtracting this from the entire spectrum as a background. A
Scheme 1. Physiologically Relevant CuII-PrP(106−115) Species at pH 7.433
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three-region polynomial spline of orders 2, 3, and 3 was used to model
the smoothly decaying postedge region. The data were normalized by
scaling the spline function to an edge jump of 1.0 at 9000 eV. This
background subtraction and normalization was done using PySpline.40
The least-squares ﬁtting program OPT in EXAFSPAK41 was used to ﬁt
the data. Initial ab initio theoretical phase and amplitude functions
were generated in FEFF 7.042 using calculated structures of CuI models
as the starting structures. Atomic coordinates were adjusted as
necessary as ﬁts were improved. During the ﬁtting process, the bond
distance (R) and the mean-square deviation or bond variance in R
arising from thermal and static disorder (σ2) were varied for all
components. The threshold energy (E0) was also allowed to vary for
each ﬁt but was constrained to the same value for all components in a
given ﬁt. Coordination numbers (N) were systematically varied to
provide the best chemically viable agreement to the EXAFS data and
their Fourier transform (FT) but were ﬁxed within a given ﬁt. The ﬁts
were evaluated based on a comparison of the normalized error (Fn) of
each ﬁt along with inspection of individual ﬁts to the data and the
agreement of the FTs and of individual wave components.
2.3. NMR Spectroscopy. CuI-PrP(106−115) complexes were
prepared as described above but at a lower peptide concentration (0.3
mM) and without glycerol, and the pH was varied from 3.4 to 9.2.
Homonuclear assignment of PrP peptides was achieved by 1H−1H
total correlated spectroscopy (TOCSY), and 1H−13C heteronuclear
single quantum coherence (HSQC) experiments were performed at
pH 6.5 and 8.5. 1H−1H TOCSY and 1H−13C HSQC cross peaks
aﬀected by CuI (0.8 equiv) were identiﬁed by comparing their
chemical shift values in the absence and presence of the metal ion. All
spectra were acquired at 288 K in NMR tubes sealed under a N2
atmosphere, using a Bruker Avance II 600 MHz spectrometer with a
triple-resonance probe equipped with z-axis self-shielded gradient
coils. Acquisition, processing, and visualization of the NMR spectra
were performed using TOPSPIN 2.1 (Bruker) and Sparky.
2.4. Electronic Structure Calculations. In all calculations, the
structure of the PrP(106−113) peptide with sequence KTNMKHMA
was used, with an acetylated N-terminus and amidated C-terminus.
The structures had a total of 141−161 atoms, depending on the
protonation state of the backbone amides and the number of explicit
water molecules included in each model. Each initial copper(I) peptide
complex model was built in GaussView 4.1.2, starting from the
previously reported CuII models.33 Using a restricted Kohn−Sham
(RKS) approach, all copper(I) peptide structures with a spin
multiplicity of 1 (singlet) were fully optimized without geometry
constraints, and the stationary points of selected CuI structures were
characterized by a harmonic analysis (Table S1 in the SI). Open-shell
calculations were done with the unrestricted Kohn−Sham (UKS)
approach. All geometry optimizations were performed using the
deMon2k code43 with the functional OPBE (which combines Handy
and Cohen’s OPTX exchange functional44 with the PBE45 correlation
functional). It should be noted that calculations at the LDA level and
with the nonempirical PBE functional were also performed for all
models; however, only the results obtained with OPBE are presented
here because this functional provides the best description and
distances for CuI−S bonds. The orbital and auxiliary basis sets used
were TZVP46,47 and GEN-A2,48,49 respectively. Solvent eﬀects on
selected optimized structures were evaluated in the deMon2k code,
including six explicit water molecules in the gas phase and
reoptimizing with OPBE and TZVP; in these cases, after
reoptimization, the water molecules remained outside the coordination
sphere (Figure S2 in the SI). Implicit solvation of selected models was
also calculated using the model COSMO,50,51 as implemented in the
ORCA52 program. Because explicit solvation with six water molecules
provides a geometric description very similar to that of implicit
solvation (Table S2 in the SI), herewith we report the results
corresponding to explicit solvation with six water molecules for all of
the structures.
The inner-sphere reorganization energy for the electron-transfer
step was computed using the following expression, which depends on
the energies of the oxidized (ox) and reduced (red) geometries at the
selected structures that best reproduce the copper complex at pH 6.5
and 8.5:53
λ = − +
−
E E E
E
1
2
[ (red ) (ox ) (ox )
(red )]
i ox geom ox geom red geom
red geom
where Eox(redgeom) is the energy of the oxidized state in the reduced
structure and Ered(oxgeom) is the energy of the reduced state in the
oxidized structure.
2.5. Stopped-Flow Kinetic Measurements. Kinetic studies of
the reduction of the copper(II) peptide complexes by ascorbate were
carried out on a SX20 stopped-ﬂow system operated by the Pro-data
software (Applied Photophysics) with a 150 W xenon light source and
equipped with a photodiode array for multiwavelength analysis. All
experiments were performed in a single-mixing mode of the
instrument, with a 1:1 (v/v) mixing ratio in a 1 cm optical path.
The temperature was maintained at 25.0 ± 0.1 °C using a water bath
and monitored via the internal sensor of the mixing unit. Data analysis
was performed with Pro-data viewer software. CuII-PrP(106−115)
complexes were degassed in a vacuum line and loaded into the driving
syringes anaerobically. All ﬂow lines of the instrument were extensively
washed with degassed sodium dithionite and 20 mM NEM/MES
buﬀer, before charging the driving syringes with reactant solutions.
The ﬁnal concentration of the copper(II) peptide complexes in the cell
Figure 1. XANES (A and D), EXAFS (B and E), and FT (C and F) spectra of CuII-PrP(106−115) (black line), CuII-PrP(106−115)M09A (green
line), CuII-PrP(106−115)M112A (red line), and CuII-PrP(106−115)M109&M112A (blue line, at pH 6.5 (A−C) and 8.5 (D−F). The parameters
obtained for the best ﬁts for these data (Figure S3 in the SI) are listed in Table 1.
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was 0.15 mM. The reduction was followed under pseudo-ﬁrst-order
conditions with a 20-fold excess of reductant, and the loss of
absorbance was monitored at 570 nm (pH 8.5) or 600 nm (pH 6.5) as
a function of time. The dead time of the measurements was 1 ms. The
reported rate constants represent the average values and standard
deviations of three independent runs.
2.6. Reoxidation Kinetic Measurements. Kinetic studies of the
reoxidation of the copper(I) peptide complexes by oxygen were
carried out on an Agilent 8453 diode-array spectrometer. All
experiments were performed in a screw-cap quartz cuvette with a 1
cm optical path. Data analysis was performed with Origin 6.1 software.
The CuI-PrP(106−115) complexes at pH 6.5 were prepared by adding
1 equiv of ascorbate to a degassed solution of the copper(II) peptide
complex (0.8 mM peptide with 0.5 equiv of copper) in 20 mM NEM/
MES; full reduction under these conditions was conﬁrmed by UV−vis
absorption. Reoxidation of the CuI complexes was followed by the
appearance of a characteristic d−d band at 600 nm after the addition
of an air-saturated buﬀer (∼0.5 equiv of dioxygen). The reported rate
constants represent average values and standard deviations of three
independent runs.
3. RESULTS AND ANALYSIS
3.1. Structure of Oxidized and Reduced Sites.
3.1.1. XAS of CuII-PrP(106−115) Complexes. The CuII-
PrP(106−115) complexes have been spectroscopically charac-
terized previously.33 The coordination mode of the CuII-
PrP(106−115) complex is pH-dependent with a pKa of 7.5. At
low pH, the equatorial coordination is the 3N1O mode, while
at high pH, a 4N coordination mode is stabilized with a third
deprotonated amide of the backbone (Scheme 1). Here, we use
XAS to evaluate these models and the role of Met109 and
Met112 in copper coordination. The Cu K-edge spectra of the
CuII-PrP(106−115) complexes at pH 6.5 and 8.5 are presented
in Figure 1. The extremely weak signal around 8979 eV is the
1s → 3d transition, associated with the CuII d9 ion. Figure 1
shows that the spectra are not aﬀected by the replacement of
Met109 and Met112 by Ala. Thus, at both pH values, the
thioether groups of the Met residues are not involved in the
coordination of CuII. EXAFS ﬁts for the data shown in Figure 1
are consistent with 4N/O tetracoordinated complexes with
Cu−ligand distances between 1.96 and 1.98 Å (Table 1 and
Figure S3 in the SI). These results are in a good agreement with
the previously proposed coordination models (Scheme 1).33
The eﬀect of the pH on the copper coordination is not
reﬂected in XAS because of the similar light-atom (N/O)
ligands at both pH values. However, the diﬀerence between the
two coordination modes (3N1O and 4N) is clearly observed by
CD and EPR.33 The reoptimized structures [from density
functional theory (DFT) calculations] of the 3N1O and 4N
models reported in ref 33 were used to simulate the EXAFS
spectra at pH 6.5 and 8.5, respectively, without any ﬁts against
the experimental data. The simulated EXAFS spectra show
reasonable frequency agreement with the experimental data
(Figure S4 in the SI), thus validating the proposed models for
the CuII-PrP(106−115) complexes in Scheme 1.
3.1.2. XAS of CuI-PrP(106−115) Complexes. The Cu K-edge
X-ray absorption near-edge structure (XANES) spectra of the
CuI-PrP(106−115) complexes show an intense signal assigned
to the electric dipole-allowed Cu 1s→ 4p transition at 8984 eV,
characteristic of CuI complexes (Figures 2A,D).54 Both XANES
and EXAFS spectra (Figure 2) of the CuI-PrP(106−115)
complexes change with the pH (Figure S5 in the SI), while the
most drastic changes are observed upon substitution of the Met
residues by Ala. Regardless of the pH, the XANES spectra of
the CuI-PrP(106−115) complex (black line) and the M109A
and M112A complexes (red and green lines) show a
characteristic signal of four-coordinate complexes (Figures
2A,D), while the CuII complex without Met residues (CuII-
Table 1. EXAFS Fits of the Spectra of CuII-PrP(106-115) and Its Met-to-Ala Variants at pH 6.5 and 8.5a
pH 6.5 pH 8.5
CuII complex coord no. path R (Å) σ2(Å2) R (Å) σ2(Å2)
CuII-PrP(106−115) 4 Cu−O/N 1.96 499 1.97 544
CuII-PrP(106−115)M109A 4 Cu−O/N 1.96 516 1.96 486
CuII-PrP(106−115)M112A 4 Cu−O/N 1.97 504 1.98 355
CuII-PrP(106−115)M109&M112A 4 Cu−O/N 1.97 505 1.96 549
aThe goodness-of-ﬁt Fn ranges between 0.19 and 0.31 depending on the signal-to-noise ratio of the data set.
Figure 2. XANES (A and D), EXAFS (B and E), and FT (C and F) spectra of CuI-PrP(106−115) (black line), CuI-PrP(106−115)M09A (green
line), CuI-PrP(106−115)M112A (red line), and CuI-PrP(106−115)M109&M112A (blue line) at pH 6.5 (A−C) and 8.5 (D−F).
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PrP(106−115)M109&M112A, blue line) displays a spectrum
indicative of a two-coordinate complex.
At pH 6.5, the EXAFS spectra (Figure 2B) of the CuI-
PrP(106−115) complex change signiﬁcantly upon each Met-to-
Ala substitution, suggesting that both Met109 and Met112
participate in CuI coordination. Consistently, the FTs of the
EXAFS spectra (Figure 2C) show a drastic loss in intensity in
the Met-to-Ala variants compared to those of the CuI-
PrP(106−115) complex; the low intensity of these signals is
best modeled by a lower number of sulfur atoms in the
coordination sphere (see below). These changes are most
dramatic for the CuI-PrP(106−115)M109&M112A complex,
consistent with the XANES results. In contrast, at pH 8.5, the
EXAFS spectra of the CuI-PrP(106−115) complex (black line)
and the single Met-to-Ala variants (red and green lines) are
practically identical (Figure 2E), while only the spectrum for
the CuI-PrP(106−115)M109&M112A (blue line), where there
are no sulfur atoms available for coordination, diﬀers from the
original complex. Consistently, the FTs of the EXAFS spectra
of CuI-PrP(106−115) (black line) and the M109A (green line)
and M112A (red line) variants (Figure 2F) are also very similar
in intensity, indicating that they have the same sulfur content in
the ﬁrst coordination sphere, while the spectrum of the CuI-
PrP(106−115)M109&M112A complex (blue line) shows
essentially no intensity at the R value of a Cu−S contribution.
Overall, the EXAFS results indicate that at pH 8.5 only one
Met residue participates in CuI coordination, while at pH 6.5,
both Met residues play an important role. Consistently, a
comparison of the spectra of the CuI-PrP(106−115) complexes
at pH 6.5 and 8.5 in Figure S5 in the SI shows diﬀerences that
can be attributed to a larger contribution of sulfur atoms in the
ﬁrst coordination sphere at low pH. The best ﬁts of the CuI-
PrP(106−115) complexes at pH 6.5 and 8.5 are shown in
Figure 3, and the corresponding parameters are listed in Table
2. At pH 6.5, the best ﬁt is achieved with two sulfur atoms at
2.37 Å and two nitrogen or oxygen ligands at 2.17 Å. The four-
coordinate nature of the complex is supported by a bond
valence sum (BVS) analysis:55−57 the BVS value is in better
agreement with a four-coordinate structure (0.98) compared to
a three-coordinate ﬁt (BVSs = 0.82). At pH 8.5, the best ﬁt of
the EXAFS data involves only one sulfur ligand at 2.35 Å and
three nitrogen or oxygen ligands displaying one short CuI−N/
O bond at 1.97 Å and two longer CuI−2N/O bonds at 2.15 Å
(Table 2). Again, BVS analysis is in better agreement with a
four-coordinate structure (BVSs = 1.10) relative to a three-
coordinate complex (BVSs = 0.74).
3.1.3. NMR Spectroscopy of CuI-PrP Complexes. In order to
further explore the nature of the ligands in the CuI-PrP(106−
115) complexes, 1D (1H) and 2D 1H−1H TOCSY and 1H−13C
HSQC experiments were carried out. The backbone amide
regions of 2D 1H−1H TOCSY and 1H−13C HSQC NMR
spectra of PrP(106−115)M109A, PrP(106−115)M112A, and
PrP(106−115) in the presence and absence of 0.8 equiv of CuI
at pH 6.5 and 8.5 were used to assign the signals of the Hε of
Met109 and Met112, the Hδ and Hε of His111, and other
residues (Figures S6−S8 in the SI). Analysis of the 1H−1H
TOCSY and 1H−13C HSQC NMR spectra shows that the most
aﬀected amino acids in the presence of CuI are Met109,
Met112, His111, and Lys110 (Figures S6−S8 in the SI). Figure
4 shows the aromatic (6.9−8.1 1H ppm) and aliphatic (1.9−2.4
1H ppm) regions of the 1H NMR spectra of the free peptide
PrP(106−115) (black line) and the CuI complex (red line) at
pH 6.5 (Figure 4A) and pH 8.5 (Figure 4B). At pH 6.5, the
chemical shifts associated with the Hε of Met109 and Met112
are clearly aﬀected (Figure 4A, aliphatic region) having a
Figure 3. EXAFS spectra (A and C) and their FTs (B and D) of CuI-PrP(106−115) at pH 6.5 (A and B) and 8.5 (C and D). Experimental data are
shown as solid black lines, and their best ﬁts, using the parameters listed in Table 2, are shown as dashed red lines.
Table 2. EXAFS Fits of Spectra of CuI-PrP(106-115)
Complexes at pH 6.5 and 8.5
pH Fn
a coord no. path R (Å) σ2 (Å2) BVS
6.5 0.579 2 Cu−O/N 2.17 126 0.98
2 Cu−S 2.37 484
8.5 0.099 1 Cu−N/O 1.97 503 1.10
2 Cu−N/O 2.15 328
1 Cu−S 2.35 421
aThe reported goodness-of-ﬁt Fn is the normalized error given by
χ χ
=
∑ −
F
k
N
( )
n
6
exptl calcd
2
data
where the summation is over the ﬁtted k range, k is the photoelectron
wave vector, and χ is the experimental or calculated data point.
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broadening and downﬁeld shift (0.15 ppm of Hε Met112 and
0.23 ppm of Hε Met109) in the presence of CuI. In agreement
with XAS data, NMR data indicate that CuI is coordinated by
both Met residues at low pH. The aromatic region of the
spectrum displays a broadening and an upﬁeld shift in the Hε
(0.12 ppm) and Hδ (0.04 ppm) signals of His111 in the
presence of CuI (Figure 4A). This result indicates that at pH
6.5 the His111 imidazole nitrogen participates in CuI binding.
At pH 8.5, in the aliphatic region of the 1H NMR spectrum,
the chemical shifts of Hε of Met109 and Met112 undergo a
broadening and a downﬁeld shift (0.12 ppm of Hε M112 and
0.21 ppm of Hε Met109) upon CuI binding (Figure 4B). In the
aromatic region, signals of the Hε and Hδ of His111 also show
broadening and downﬁeld shift. The eﬀect of CuI on the signals
of the Hε and Hδ of His111 suggests that at pH 8.5 the His111
imidazole nitrogen participates in CuI binding. However, the
line broadening observed at pH 8.5 in both regions is much
more dramatic than that observed at pH 6.5. Such large signal
broadening may be related to the presence of two species at pH
8.5, one with the sulfur atom from Met109 coordinating CuI
and another complex with the sulfur atom from Met112. This
interpretation is consistent with the behavior of the Met-to-Ala
variants observed in XAS, where the only sulfur available in
each variant is found to coordinate CuI. In summary, our NMR
data corroborate the involvement of sulfur atoms from Met109
and Met112 of the PrP(106−115) fragment in the coordination
of CuI, while they clearly indicate that the His111 imidazole
nitrogen also binds to the metal ion.
3.1.4. Eﬀect of the pH on the CuI-PrP(106−115) Complex
Followed by NMR Spectroscopy. To further explore the role
that Met109, Met112, and His111 play on the coordination
with CuI, we tested both the PrP(106−115) peptide and the
CuI-PrP(106−115) complex by 1H NMR spectroscopy at
several pH values ranging from 3.5 to 9.5. Figure 5A shows the
behavior of Hε (dashed black line) and Hδ (solid black line) of
His111 in the free peptide and in the CuI-PrP(106−115)
complex (dashed and solid red lines). The pKa associated with
the free histidine is 6.2, while in the presence of CuI, the pKa of
histidine shifts to ∼5 because of the coordination of His111 to
CuI in the CuI-PrP(106−115) complex. This shift is consistent
with that observed in CuI complexes in blue copper
proteins.58−60 The signals associated with the Met residues in
the CuI-PrP(106−115) complex also change drastically with
the pH. Figure 5B shows in green (Hε Met109) and red (Hε
Met112) dots chemical shifts of Hε of Met109 and Met112 in
the presence of CuI at several pH values (3.5−9.5). The
chemical shift of these protons is 2.10 ppm in the free peptide
(Figure 4), and they do not change with the pH (data not
shown). However, in the presence of CuI, even at a pH as low
as 3.5, the signals associated with Hε of Met109 and Met112
are both shifted to 2.29 ppm, indicating coordination to CuI.
Also, at higher pH values (above 8.5), both signals show a
tendency to return to the chemical shift associated with the free
peptide (2.10 ppm). This result indicates that, at higher pH
values, both Met residues leave the coordination sphere of CuI,
leading to a species without thioether ligands; such species
would not be physiologically relevant and were not further
characterized.
These NMR data provide further insight into the role of
Met109, Met112, and His111 in the coordination of CuI to the
PrP(106−115) fragment as a function of the pH. At very low
pH (3.5), CuI is coordinated by both Met109 and Met112.
With a pKa of ∼5, the nitrogen imidazole from His111 enters
the coordination sphere, while the two Met residues remain
coordinated. As the pH is further increased, the Met residues
play a less important role in CuI coordination, and only one
Met residue (Met109 or Met112) coordinates CuI at pH >8
(Scheme 2).
3.1.5. DFT Modeling. The “box” in Scheme 2 shows the
structures for the CuI-PrP(106−115) complexes under
extracellular conditions, derived from the EXAFS and NMR
data. In order to gain further insight into the nature of the
Figure 4. 1H NMR spectra of PrP(106−115) (black line) and CuI-
PrP(106−115) (red line) at pH 6.5 (A) and 8.5 (B). Black lines
indicate the chemical shifts for the Hε protons of Met residues and the
Hε and Hδ protons of histidine in the peptide without copper. Gray
arrows show the shifts of these signals in the presence of CuI.
Figure 5. (A) Chemical shifts of the Hε and Hδ protons of His111 in the free peptide (dashed and solid black lines) and in the CuI-PrP(106−115)
complex (dashed and solid red lines) as a function of the pH. A shift in the pKa of His111 is observed in the presence of Cu
I. (B) Chemical shifts of
the Hε protons of Met109 (green dots) and Met112 (red dots) in the CuI-PrP(106−115) complex as a function of the pH. The pH-independent
chemical shift of these protons is 2.10 ppm in the free peptide.
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unidentiﬁed N/O ligands in these CuI complexes, several
models were built and RKS calculations were performed, using
the CuII models previously described as starting points.33 The
copper ion was reduced and three groups of ligands were
evaluated (Table S3 in the SI). Group 1 included four-
coordinate CuI-1N2S1x models for the complex formed at pH
6.5, with two sulfur atoms from both Met residues (Met109
and Met112), a His111 imidazole nitrogen, and a fourth ligand
x, where x could be an oxygen atom from a backbone carbonyl
group, a solvent H2O molecule, or a nitrogen atom from a
backbone amide in a protonated (N) or deprotonated form
(N−) (including those of the most aﬀected amino acid residues
in the 2D TOCSY and HSQC experiments; Figures S6−S8 in
the SI). Because at pH 8.5 the EXAFS results indicate that one
Met is coordinated while NMR data show that both Met
residues are aﬀected, group 2 included four-coordinate CuI-
1N1S2x models, where the sulfur atom is provided by either
Met109 (group 2A) or Met112 (group 2B), His111 imidazole
provides a nitrogen ligand, and 2x could be any of the following
combinations: 2N−, 1N1N−, 2N, 1N−1O, 1N1O, or 2O
(described above). It should be noted that, because the
XANES data indicate that CuI complexes are four-coordinate,
only the structures that optimized as four-coordinate complexes
were analyzed in each group.
3.1.5.1. CuI Structures at pH 6.5 (CuI-1N2S1x Models). Five
structures optimized as four-coordinate complexes in group 1
(Table S3 in the SI); these are shown in Figure 6, and relevant
geometric parameters with and without solvent eﬀects are listed
in Table S4 in the SI. The group 1 models are divided into two
subgroups, according to the total number of atoms (160 or
161), which depends on the protonation state of the backbone
amides. In this group, when x is a deprotonated amide (2N2Sa
and 2N2Sb), the average CuI−S bond distances (2.365 and
2.34 Å) are in good agreement with the experimental values;
however, the two Cu−N bonds are quite short (2.09−2.10 Å).
When x is a backbone carbonyl (1N1O2Sa and 1N1O2Sb) or a
water molecule (1N1O2Sc1), the average CuI−S bond lengths
(2.35, 2.34, and 2.36 Å) and CuI−N/O distances are in good
agreement with the experimental data (2.17, 2.145, and 2.16 Å;
Table S4 in the SI). However, the 1N1O2Sb model is discarded
because it is the structure that has the highest energy in this
subgroup, 13.32 kcal/mol above 1N1O2Sa.
Thus, the best candidates for the pH 6.5 CuI structures
(group 1) are the 1N1O2Sa and 1N1O2Sc1 models (Figure 6)
because they display metal−ligand distances that best
reproduce the experimental data in trends and values.
Furthermore, using 1N1O2Sc1 to simulate an EXAFS spectrum
using the EXAFSPAK program yielded a spectrum that was in
good intensity agreement (but indicating an overall longer
distance) with the experimental data for CuI-PrP(106−115) at
pH 6.5 (Figure S9 in the SI). Therefore, at pH 6.5 the best
model to represent the CuI-PrP(106−115) complex has two
sulfur atoms from Met109 and Met112, a His111 imidazole
nitrogen, and an oxygen atom as the fourth ligand, which could
be the carbonyl oxygen atom from His111 (as in model
1N1O2Sa) or a water molecule (as in model 1N1O2Sc1).
3.1.5.2. CuI Structures at pH 8.5 (CuI-1N1S2x Models). In
these models, the sulfur atom can be provided by Met109
(group 2A) or Met112 (group 2B). The group 2 models are
divided into two subgroups, according to the total number of
atoms (159 or 160), which depends on the protonation state of
the backbone amides. Five structures optimized as four-
coordinate complexes in group 2A and only four in group 2B
(Table S3 in the SI). The structures are shown in Figure 7, and
their geometric parameters with and without solvent eﬀects are
listed in Tables S5 and S6 in the SI.
For the models with Met109, when 2x is a combination of
two deprotonated amides (3N1SM109a and 3N1SM109c), only
the 3N1SM109c model yields Cu−ligand distances that are in
agreement with the experimental trend, one short Cu−N and
two long Cu−N bonds (2.04 and 2.13 Å, respectively) and a
CuI−S bond distance at 2.36 Å (Table S5 in the SI), although it
is the highest-energy structure of the group (Figure 7). In
contrast, in the models where 2x is the combination of a
deprotonated amide and a backbone carbonyl (2N1O1SM109a,
2N1O1SM109b, and 2N1O1SM109c), the Cu
I−S bond and the
Scheme 2. Proposed Coordination Models for the CuI-PrP(106−115) at Several pH Values, Based on XAS and NMR Dataa
aAt pH <5, CuI is anchored by both Met residues, while at a pH >5, the His111 imidazole also participates in CuI coordination. At pH >8, only one
Met residue coordinates CuI. The “box” shows extracellular species.
Figure 6. Energy diagram of optimized four-coordinate CuI-1N2S1x
models for the CuI-PrP(106−115) complex at pH 6.5 (group 1), with
explicit solvent. Most side chains are not shown for clarity; however,
the geometry optimizations were done with the complete CuI-
PrP(106−113) complex.
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trend of a short Cu−N and two long Cu−N/O bonds are
reproduced in the 2N1O1SM109a model (2.32, 2.02, and 2.15 Å,
respectively; Table S5 in the SI), which is the lowest-energy
structure in this subgroup. Thus, we propose that the best
model for the CuI-PrP(106−115) complex at pH 8.5 with a
sulfur atom from Met109 is 2N1O1SM109a, with a nitrogen
atom from the deprotonated amide of Lys110 and an oxygen
atom from the carbonyl of His111.
The CuI-1N1S2x models with the Met112 ligand (Figure 7
and Table S6 in the SI), having 2x as a combination of two
deprotonated amides (3N1SM112a and 3N1SM112c), yield a
CuI−S bond at 2.28−2.30 Å and three similar Cu−N bonds
(∼2.03−2.04 Å), which is not consistent with the experimental
trend. On the other hand, when 2x is a combination of a
deprotonated amide and a backbone carbonyl (2N1O1SM112a
and 2N1O1SM112d), the 2N1O1SM112d model leads to a three-
coordinate structure, while the Cu−ligand distances in the
2N1O1SM112a model show excellent agreement with the
experimental data: a short Cu−N bond (2.00 Å), two long
Cu−N/O bonds (2.17 Å), and a CuI−S bond at 2.34 Å (Table
S6 in the SI). Therefore, the best model for the CuI-PrP(106−
115) complex with Met112 at pH 8.5 is the 2N1O1SM112a
structure.
Overall, the best models for the CuI-PrP(106−115) complex
at pH 8.5 are 2N1O1S structures with a nitrogen from the
deprotonated backbone amide of Lys110 and an oxygen from
the backbone carbonyl of His111, regardless of which Met
participates in the coordination shell.
Figure 8 summarizes the results from DFT modeling,
showing the best models for the CuII and CuI complexes
with PrP(106−115) at pH 6.5 and 8.5. It is clear that the CuII
complexes (CuII-3N1O and CuII-4N) have very diﬀerent
geometries and coordination spheres than their reduced
counterparts (CuI-1N1O2S and CuI-2N1O1S). Thus, the
reduction of these complexes would involve a large
reorganization energy. We calculated the inner-sphere reorgan-
ization energies associated with the reduction of the CuII
species to CuI, at pH 6.5 and 8.5. For the low-pH structures
CuII-3N1O and CuI-1N1O2S, the calculated λi is 1.79 eV when
the oxygen ligand is the backbone carbonyl of His111 and 2.15
eV when it is a water molecule. At pH 8.5, the CuII-4N and CuI-
2N1O1S structures yielded a reorganization energy of 1.60 eV
when Met109 is bound and 1.66 eV for the Met112 structure
(Table S7 in the SI). These are necessary for evaluating the
reduction and O2 reactivity in the next section.
3.2. Reactivity. Once the geometries and electronic
structures of the CuI-PrP(106−115) complexes had been
elucidated, we evaluated the role of Met109 and Met112 on the
reactivity of these complexes. First, the kinetics of reduction of
the CuII-PrP(106−115) complexes with ascorbate was studied,
followed by reactivity studies of the resultant CuI-PrP(106−
115) complexes with dioxygen.
3.2.1. Reduction of CuII-PrP(106−115) Complexes. The
reduction of both complexes CuII-3N1O at pH 6.5 and CuII-4N
at pH 8.5 by ascorbate was examined by stopped-ﬂow
absorption spectroscopy at 25 °C. Electronic absorption at
the wavelength for the maximum intensity of the ligand-ﬁeld
transitions (i.e., 600 nm at pH 6.5 and 570 nm at pH 8.5) was
followed over time after rapid mixing of the CuII complexes
with the reductant. The reduction was followed under pseudo-
ﬁrst-order conditions, using at least a 20-fold excess of the
reductant over the copper complex concentration. Plots of the
absorption intensity at 600 and 570 nm as a function of the
reaction time are shown in Figure 9, while representative data
for the absorption spectra are shown in the insets; ﬁts to the
kinetic traces are summarized in Table 3. The reduction of the
CuII-3N1O complex at pH 6.5 can be ﬁtted to a single-
exponential equation to obtain kobs = 0.287 ± 0.010 s
−1 (Figure
9A). In contrast, the reduction of CuII-4N complex at pH 8.5
exhibited a slow biphasic behavior (Figure 9B). The kinetic
trace for CuII-4N can be ﬁtted to a double-exponential
equation, yielding rates of 0.134 ± 0.023 and 0.010 ± 0.004
s−1. Thus, even the fast phase of reduction of the CuII-4N
complex at pH 8.5 is 2-fold slower than reduction of the CuII-
3N1O complex at pH 6.5 (Table 3). Considering the
reorganization energies calculated for these two complexes,
one would expect the opposite trend because λ3N1O is higher
than λ4N. This could be due to a diﬀerence in the reduction
potentials of the CuII-3N1O and CuII-4N species, which would
result in diﬀerent driving forces for the two reactions. Using
anaerobic reductive titrations of the CuII complexes at pH 6.5
and 8.5 with ascorbate, we estimate a reduction potential of
∼152 mV for the CuII-3N1O complex and ∼75 mV for the
Figure 7. Energy diagram of optimized four-coordinate CuI-1N1S2x
models for the CuI-PrP(106−115) complexes at pH 8.5, with explicit
solvent and either Met109 (group 2A) or Met112 (group 2B) as the
ligand. Most side chains are not shown for clarity; however, the
geometry optimizations were done with the complete CuI-PrP(106−
113) complex.
Figure 8. DFT-derived models for CuII and CuI complexes with the
PrP(106−115) peptide at diﬀerent pH values. For the CuI complex at
pH 6.5, the best model has a 1N1O2S coordination sphere, where
both Met residues are bound to copper and the oxygen atom can be
the carbonyl oxygen from His111 (as shown here) or a water
molecule. At pH 8.5, the best models are 2N1O1S structures with a
deprotonated amide of Lys110, an oxygen atom from the backbone
carbonyl of His111, and either Met109 or Met112 as the sulfur ligand.
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CuII-4N complex. Thus, a signiﬁcant diﬀerence in ΔG° for their
reduction by ascorbate is expected {ΔΔG° = [ΔG°(3N1O) −
ΔG°(4N)] = −3.52 kcal/mol}. Using the semiclassical Marcus
equation for the rate of intermolecular electron transfer and
considering the diﬀerences in the reorganization energies and
reduction potentials, the ratio of the reduction rates for CuII-
3N1O and CuII-4N species is calculated to be k3N1O/k4N = 2.3
(see the SI), which is consistent with the experimental values.
Thus, the diﬀerence in the reduction potentials for these two
complexes results in a faster reduction for the CuII-3N1O
complex compared to that for the CuII-4N species.
In order to evaluate the eﬀect of Met109 and Met112 on the
rate of reduction of the CuII-3N1O complex, the reduction of
the CuII-PrP(106−115)M109A, CuII-PrP(106−115)M112A,
and CuII-PrP(106−115)M109&M112A complexes by ascor-
bate at pH 6.5 was also studied; representative kinetic traces are
shown in Figure S10 in the SI, and the reduction rates are
summarized in Table 3. Within experimental error, CuII-
PrP(106−115)M109A, CuII-PrP(106−115)M112A, and CuII-
PrP(106−115)M10&M112A exhibit a reduction rate constant
that is the same as that of the CuII-PrP(106−115) complex.
These results suggest that the Met residues are not involved in
the rate-limiting step of the reduction of the CuII-PrP(106−
115) complex at pH 6.5. Thus, it is likely that this involves
electron transfer, followed by a slower rearrangement of the
peptide, to provide the Met ligands to form the pH 6.5 CuI-
1N1O2S complex.
3.2.2. Reoxidation of CuI-PrP(106−115) Complexes with
Dioxygen at pH 6.5. We next investigated the ﬁrst step of
dioxygen activation by the CuI-PrP(106−115) complexes.
Reduced complexes of PrP(106−115), PrP(106−115)M109A,
PrP(106−115)M112A, and PrP(106−115)M10&M112A were
mixed with an oxygenated buﬀer, and the reaction was followed
by UV−vis absorption spectroscopy. Figure 10 shows the time
traces for the appearance of the d−d transition, indicating CuII
oxidation, while the reoxidation rate for each copper peptide is
listed in Table 4. The end products of the reaction of CuI-
PrP(106−115) complexes with oxygen were spectroscopically
characterized by CD and EPR; in all cases, at least 50% of the
original CuII complexes were recovered (Figure S11 in the SI).
Figure 9. Stopped-ﬂow absorption data for the reduction of the CuII-PrP(106−115) complex at pH 6.5 (3N1O complex) (A) and at pH 8.5 (4N
complex) (B) with 20 equiv of ascorbate. Representative absorption traces, showing the loss of intensity of the d−d transitions as a function of time,
are shown in each inset.
Table 3. First-Order Rate Constants for the Reduction of CuII-PrP(106−115) Complexes at pH 6.5 and 8.5 and Their Met-to-
Ala Variants
ﬁrst-order rate constant (s−1)
peptide complex pH fast phase slow phase
PrP(106−115) CuII-4N 8.5 0.134 ± 0.023 0.010 ± 0.004
PrP(106−115) CuII-3N1O 6.5 0.287 ± 0.010
PrP(106−115)M109A CuII-3N1O 6.5 0.295 ± 0.027
PrP(106−115)M112A CuII-3N1O 6.5 0.318 ± 0.024
PrP(106−115)M109&M112A CuII-3N1O 6.5 0.327 ± 0.023
Figure 10. Kinetic traces for the reoxidation by dioxygen of the CuI-
PrP(106−115) complex (black) and the variants CuI-PrP(106−
115)M109A (green), CuI-PrP(106−115)M112A (red), and CuI-
PrP(106−115)M109&M112A (blue) at pH 6.5, followed by UV−vis
absorption spectroscopy at 600 nm. Inset: Representative absorption
data showing the increase in the intensity of the ligand-ﬁeld transitions
for the CuII complex as a function of time.
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Also, analysis of the samples by matrix-assisted laser
desorption/ionization time of ﬂight/time of ﬂight (MALDI-
TOF/TOF) showed metal-catalyzed oxidation for the
PrP(106−115), PrP(106−115)M109A, and PrP(106−
115)M112A peptides (Figure S12 in the SI). In particular, for
the PrP(106−115) peptide, two new signals with m/z peaks
corresponding to the mass of the peptide, +16 and +32 Da,
were observed, while single-variant peptides [PrP(106−
115)M109A and PrP(106−115)M112A] only show one +16
Da peak. In contrast, the double-variant PrP(106−115)-
M109&M112A peptide, which contains no Met residues,
suﬀered no modiﬁcation. These results indicate that redox
cycling of these copper peptide complexes results in oxidation
of the Met residues into sulfoxides, while no evidence was
found for their oxidation to sulfone.
The reoxidation of CuI-PrP(106−115) by dioxygen may
follow inner- or outer-sphere electron-transfer pathways. In an
outer-sphere mechanism, the CuI complex would be oxidized
by dioxygen in a single step to regenerate the CuII complex,
while an inner-sphere reaction would involve binding of
dioxygen to the CuI complex and formation of a potential
copper(II) superoxide intermediate, followed by the release of
superoxide to regenerate the CuII complex. The possibility of
outer-sphere reoxidation of the CuI-PrP(106−115) complexes
was evaluated using the Marcus equation to analyze the rates in
Table 4.61,62 Using an estimated reduction potential for the
copper peptide complex of 150 mV, the potential of one-
electron reduction of dioxygen to O2
•− (−165 mV vs NHE),63
and the calculated reorganization energy of the site, the outer-
sphere electron-transfer rate from the CuI complex at pH 6.5 to
Table 4. First-Order Rate Constants for Reoxidation by
Dioxygen of the CuI-PrP(106−115) Complex and Its Met-
to-Ala Variants at pH 6.5
complex ﬁrst-order rate constant (min−1)
CuI-PrP(106−115) 0.218 ± 0.005
CuI-PrP(106−115)M109A 0.425 ± 0.060
CuI-PrP(106−115)M112A 0.421 ± 0.009
CuI-PrP(106−115)M109&M112A 2.582 ± 0.154
Figure 11. Schematic representation of the main Cu-PrPC complexes under diﬀerent physiological conditions. (A) At low CuII concentration (nM),
CuII would be anchored at the OR (CuII-OR) and at His96 and His111 sites (CuII-3N1O and CuII-4N). (B) CuII complexes in the presence of
reducing agents would be reduced. At the His111 site, the most abundant species would be CuI-1N1O2S. (C) High copper concentrations (100−
500 μM) can stimulate endocytosis; in the endosomes, only the His111 site would coordinate CuI through Met109 and Met112. (D) In the
extracellular space, oxygen activation by copper bound to His111 could generate superoxide, causing the subsequent oxidation of Met residues.
Footnotes: a, ref 27; b, ref 28; c, ref 33; d, this work; e, ref 34; f, ref 35.
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the oxygen molecule is estimated to be at most ∼2.81 × 10−4
s−1 (see the SI), which is 10−102 times slower than the
experimental rate of CuI reoxidation from the kinetic data (3.6
× 10−3). Thus, single-electron transfer from CuI-PrP(106−115)
to dioxygen likely proceeds via an inner-sphere pathway that
would involve formation of a copper(II) superoxide species.
This is consistent with a previous study that showed the
formation of superoxide species upon redox cycling of the Cu-
PrP(106−114) complex35 and with our ﬁnding that the Met
residues are oxidized to sulfoxides upon redox cycling of the
CuI-PrP(106−115) complex.
It is important to note that the reoxidation rate shows an
inverse correlation to the number of Met residues in the initial
CuI complex, following the trend CuI-PrP(106−115) < CuI-
PrP(106−115)M109A ∼ CuI-PrP(106−115)M112A < CuI-
PrP(106−115)M109&M112A (Table 4). The reoxidation rate
of the CuI-PrP(106−115)M109&M112A complex is 6 times
faster than those of the single variants and 10 times faster than
that of the CuI-PrP(106−115) complex containing both Met
residues. These results suggest that the presence of Met ligands
at the CuI complex aﬀects the rate-limiting step in the
reoxidation process, which likely involves formation of the
copper(II) superoxide species. XANES data clearly show that,
in the absence of Met residues, the CuI-PrP(106−115)-
M109&M112A complex is two-coordinate, while the CuI-
PrP(106−115) complex is four-coordinate (vide supra). Thus,
in an associative mechanism for formation of the copper(II)
superoxide species, a faster reaction would be expected for the
CuI-PrP(106−115)M109&M112A complex because of its
coordination unsaturation, as observed. The nature of the
mechanism (associative vs dissociative) for the inner-sphere
oxygen reaction of the four-coordinate CuI-PrP(106−115)
complex requires further computational evaluation.
4. DISCUSSION
4.1. Copper Binding to His111. CuII-PrP(106−115)
complexes at pH 6.5 and 8.5 were studied by XAS, and the
role of Met109 and Met112 in CuII coordination was evaluated
using peptides with Met-to-Ala variants. Our XAS results show
that CuII coordination to His111 occurs through nitrogen and
oxygen atoms at low pH, and all nitrogen ligation at high pH
(pKa = 7.5), which is consistent with the previously proposed
coordination models, as shown in Scheme 1,33 while the
possibility of Met residues acting as ligands for CuII can be
discarded. XAS and NMR spectroscopy, in combination with
electronic structure calculations, show that CuI coordination to
PrP(106−115) is also pH-dependent (Scheme 2). At pH <5,
the thioether groups of Met109 and Met112 bind CuI; with a
pKa of ∼5, the nitrogen imidazole from His111 enters the
coordination sphere, while both Met residues remain
coordinated, adopting a 1N1O2S coordination mode. At pH
8.5, two CuI species with 2N1O1S (2NOSM109 and 2NOSM112)
coordination modes are formed, with a single Met residue
bound to CuI (Scheme 2). Although this study has used a short
fragment of PrP that only includes His111, the 2S and 1N1O2S
species described here would form in longer PrP protein chains.
At low pH (below 5), all His residues would be protonated and
Met109 and Met112 would dominate CuI coordination to form
the 2S species. At higher pH, other N-terminal His residues,
such as His96, could participate in CuI binding; however, a
recent study of CuI and AgI coordination to the 91−127
fragments demonstrated that a helical structure at the
hydrophobic region of the 91−127 fragments causes His96 to
fall out of the coordination sphere, leaving His111 as the main
copper anchoring site;64 thus, the 1N1O2S complex described
herein would be the dominant species.
PrPC is a synaptic glycolipid-anchored membrane protein
predominantly expressed on presynaptic membranes,65 where it
is exposed to CuII ions in a range of concentrations: from 15
μM at the synaptic cleft during synaptic vesicle release up to
100−300 μM during neuronal depolarization.66,67 Thus, PrPC
can interact with CuII ions in the extracellular space, and at pH
7.4, there is a mixture of two species 3N1O and 4N (Scheme 1
and Figure 11A). Also, biological reductants, such as ascorbic
acid, are found in concentrations of 150 μM in the
cerebrospinal ﬂuid.68,69 Thus, CuII-PrP complexes anchored at
His111 in the synaptic cleft may be reduced to CuI by available
reducing agents. Our results indicate that, in the presence of
ascorbate, the CuII-3N1O complex would reduce faster to
generate a CuI-1N1O2S complex. Therefore, at physiological
pH, 3N1O and 4N complexes are the relevant CuII species,
while the 1N1O2S complex is the relevant CuI coordination
mode at the His111 site in PrPC (Figure 11B).
Unlike all other copper binding sites in the human PrP
protein, the His111 binding site contains the MKHM motif,
which provides it with unique coordination and redox
properties. MX2MX2M motifs have been identiﬁed in copper-
transport proteins (e.g., Yeast yCtr1) that bind CuI selectively
via Met residues with aﬃnities in each motif on the order of
∼2.5 × 10−6 M at pH 4.5.70 On the other hand, several proteins
involved in copper transport that utilize His in combination
with Met residues for CuI binding have emerged, such as PcoC
with a CuI-(His)(Met)2 coordination mode,
71 CopC [CuI-
(His)(Met)3; KD ∼ 10−13 M],72,73 and CusF [CuI-(His)-
(Met)2(O)].
74 In these cases, the presence of the His residue in
the coordination sphere plays two roles: (i) to increase the
aﬃnity for CuI and (ii) to enable the coordination of CuII
ions.75,76 Furthermore, it has been demonstrated that thioether
ligands can be particularly eﬀective at chelating CuI when they
are separated by no more than two amino acids.70 The MKHM
motif in the human PrP(106−115) sequence fulﬁlls these
conditions, such that at physiological pH CuII can be anchored
via the His residue, while upon reduction, the CuI ion is bound
by His and Met residues. High CuII concentrations stimulate
endocytosis of the prion protein,21,23 taking the protein from
the extracellular space at pH 7.4 to the endosomal space, where
there is a high concentration of protons (pH 4−5) and
biological reductants, such as glutathione or nicotinamide
adenine dinucleotide (NADH), that are found in concen-
trations of 1−3 mM and ∼200 μM, respectively.77,78 Under
these conditions, His111 would be protonated and CuI would
be anchored only by Met residues, as illustrated in Figure 11C.
Thus, this site is optimized to chelate both CuII and CuI ions
and is likely to be involved in CuI transport into the cell.
4.2. Reactivity. CuII and CuI bound to PrP(106−115) form
complexes with very diﬀerent geometries and coordination
spheres: CuII-3N1O versus CuI-1N1O2S at pH 6.5 and CuII-4N
versus CuI-2N1O1S at pH 8.5, resulting in large reorganization
energies of the site upon reduction of 1.79 and 1.6 eV,
respectively. In spite of its higher reorganization energy,
reduction of the CuII-3N1O complex is faster than that of
the CuII-4N species because of its higher reduction potential.
Considering that, at physiological pH, CuII-3N1O and CuII-4N
complexes are present, our results indicate that, under reducing
conditions, the CuII-3N1O complex would reduce faster,
shifting the equilibrium between 3N1O and 4N toward the
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CuII-3N1O complex and favoring production of the CuI-
1N1O2S complex.
Overall, the reorganization energies for the Cu-PrP(106−
115) complexes are large compared to those of copper sites
that are optimized to support electron transfer (blue copper T1
and CuA sites), which range from 0.5 to 0.82 eV.
79−81 Despite
its large reorganization energy, the CuI-PrP(106−115) complex
still reacts with dioxygen. Several studies regarding the redox
activity and functional implications of Cu-PrPC complexes have
been put forward.35−37,82−85 Some studies have reported the
generation of reactive oxygen species (H2O2 or superoxide) by
Cu-PrP complexes;34−36,83,84,86 however, little is known about
the mechanism of dioxygen activation by the diﬀerent Cu-PrP
complexes. This study investigated the kinetics of the ﬁrst step
of dioxygen activation by the CuI-1N1O2S complex at pH 6.5.
The reoxidation rate is highly dependent on the presence of the
Met residues. The estimate for the rate of outer-sphere
reoxidation is 102 times slower than the experimental rate of
CuI reoxidation from the kinetic data. Thus, we conclude that
the CuI-1N1O2S complex at the His111 site reacts with
dioxygen in an inner-sphere electron-transfer pathway that
involves binding of dioxygen to the CuI complex and formation
of a copper(II) superoxide intermediate, followed by the release
of superoxide and partial regeneration of the CuII complex.
Our study also shows that the Met residues can be selectively
oxidized to sulfoxide by the copper-catalyzed reaction (Figure
11D). It has been proposed that copper-catalyzed oxidation of
Met residues may trigger a structural transition, leading to
aggregation of PrP protein,87,88 or it may interfere with
conversion of the prion protein into the ﬁbrillar proteinase K-
resistant conformation.89 Beyond that, Met residues in PrPC
may act as an innate antioxidant defense in the protein by their
ability to scavenge the produced superoxide and undergo
oxidation to form methionine sulfoxide. Without the Met
residues, the produced superoxide would produce cell damage.
The enzymatic peptide methionine sulfoxide reductase (MsrA)
reverses methionine sulfoxide back to Met, which once again is
able to scavenge oxidants.90 In fact, in the Alzheimer’s disease
brain, a decrease in the activity of MsrA compared to control
subjects was observed,91 while the induction of MsrA activity
protects neuronal cells from Amyloid β toxicity.92 It is plausible
that a reversible oxidation/reduction of Met residues at the N-
terminal region of the PrPC protein could be acting as an ROS
sink. This would be consistent with the notion that PrPC plays a
role in cellular antioxidant defense.93
5. CONCLUSIONS
In summary, our study shows that CuI binding to His111 is
highly pH-dependent and that the presence of one His and two
Met residues in the MKHM motif of the human PrP(106−115)
fragment confers this site with unique CuI binding properties.
Even upon drastic changes in the chemical environment, in
particular those occurring during endocytosis, the two Met
residues in the MKHM motif allow PrPC to keep CuI ions
anchored, consistent with a copper-transport function for this
protein. On the other hand, in the extracellular space, in the
presence of reducing agents, the most populated CuI-His111
complex would be a CuI-1N1O2S species, which is capable of
activating dioxygen. Our study provides further insight into the
molecular mechanism of oxygen activation by this site. The
CuI-1N1O2S complex reacts with dioxygen through an inner-
sphere mechanism, likely involving the formation of a
copper(II) superoxide intermediate, followed by the release
of superoxide and partial regeneration of the CuII complex. The
Met residues are oxidized to sulfoxide in this process, and their
ability to scavenge superoxide may play a role in the proposed
antioxidant properties of PrPC.
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